The Koxing Bio23 price pneumonia vaccine has been approved for sale in China

On December 9, Koxing Holding Biotechnology Co., Ltd. announced that the 23-price pneumococcal polysaccharide vaccine (the "23-price pneumococcal vaccine") developed by its subsidiary, Coxing Biotech, had been approved by the State Drug Administration of China (NMPA) on December 2 for the "Drug Registration Approval" (approval number: National Drug Code S20200027), which will be released soon.
23-price pneumococcal polysaccharide vaccine project was launched in 2009 and phase 3 clinical studies were completed in April 2017.
clinical results show that the vaccine is immunogenic and safe.
the vaccine is intended for people 2 years and older with an increased risk of pneumococcal infection and is used to prevent infectious diseases caused by the 23 serotype pneumococcal species mentioned above.
23 pneumococcal polysaccharide vaccine is the first bacterial vaccine product approved for sale by Koxing Bio.
the vaccine, which does not add preservatives, is one of the few 23-price pneumococcal polysaccharide vaccines in the world with pre-filled syringes and xilin bottles.
it uses 23 widespread and invasive serotypes, including serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14 , 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F, respectively, cultured, inactivated and purified 23 serotonin-type pneumococcal membrane polysaccharide antigens, mixed and divided into.
all quality control standards for the vaccine meet or are better than those of the Chinese Pharmacopeia and the European Union Pharmacopeia.
pneumococcus has multiple serotonin types, spread by droplets from person to person, fixed in the nasopharyngeal part of the human body.
commonly carry pneumococcal bacteria in healthy people, with high risk of disease in winter and early spring.
pneumococcal infections can cause a variety of invasive and non-invasive diseases, including pneumonia, meningitis, bacteremia and otitis middle, with a high risk of mild and severe illness.
addition, mixed infections are a potential hazard of pneumococcal diseases.
that pneumococcal bacteria may be infected with chyrobacteria, mycosms, other bacteria, viruses.
Consensus of Experts on Immunization Against Pneumococcal Diseases (2020 edition) recommends that it is necessary and urgent to use pneumococcal vaccine to prevent pneumococcal diseases.
23-price pneumococcal polysaccharide vaccine can cover more than 85% of the disease-caused serotoning, is currently on the market one of the most widely protected pneumococcal vaccine.
: The 23-price pneumococcal polysaccharide vaccine developed by Beijing Science and Technology Products Co., Ltd. was approved for sale. Retrieved 2020-12-09, from Source: Supplied